Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.56 USD | +0.79% | +10.34% | -87.51% |
03/04 | North American Morning Briefing : Powell Awaited -2- | DJ |
02/04 | JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform | MT |
Business Summary
Number of employees: 41
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 01/17/01 | |
Eric Easom
FOU | Founder | 56 | 01/17/01 |
Lucy Day
DFI | Director of Finance/CFO | 65 | 01/19/01 |
Paul Eckburg
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/19/01 |
Jennifer Huber
LAW | General Counsel | - | - |
Josh Eizen
LAW | General Counsel | - | - |
Corporate Officer/Principal | - | 01/19/01 | |
Kevin Krause
PRN | Corporate Officer/Principal | 49 | 01/21/01 |
Annie Yoshiyama
AUD | Comptroller/Controller/Auditor | 41 | 15/23/15 |
Sanjay Chanda
PRN | Corporate Officer/Principal | 59 | 01/19/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 60 | 01/17/01 | |
Patricia Martin
BRD | Director/Board Member | 63 | 01/21/01 |
Melvin Spigelman
BRD | Director/Board Member | 75 | 01/22/01 |
Director/Board Member | 58 | 09/22/09 | |
Robin Readnour
BRD | Director/Board Member | 59 | 01/19/01 |
Stephanie Wong
BRD | Director/Board Member | 50 | 01/21/01 |
Kabeer Aziz
BRD | Director/Board Member | 34 | 01/19/01 |
Eric Easom
FOU | Founder | 56 | 01/17/01 |
Gilbert Marks
BRD | Director/Board Member | 66 | 01/20/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 29,829,040 | 22,107,490 ( 74.11 %) | 0 | 74.11 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.51% | 76.36M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- ANTX Stock
- Company AN2 Therapeutics, Inc.